Compugen announced it will present two posters with new data on COM701, the Company’s first-in class immuno-oncology therapeutic antibody candidate targeting PVRIG, and COM902.
Two poster presentations will present new COM701 and COM902 data
Compugen (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced it will present two posters with new data on COM701, the Company’s first-in class immuno-oncology therapeutic antibody candidate targeting PVRIG, and COM902, the Company’s immuno-oncology therapeutic antibody targeting TIGIT, at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer to be held November 8-12 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.
The poster titled “Analysis of the TIGIT/PVRIG axis in human cancers to support indication selection and biomarkers for COM701 and COM902" (Poster no. P369) will be presented on Friday, November 10, 2017 at 12:30-2 pm and 6:30-8 pm ET.
The poster titled “Development and functional characterization of COM902, a novel therapeutic antibody targeting the immune checkpoint TIGIT” (Poster no. P344) will be presented on Saturday, November 11, 2017 at 12:30-2 pm and 6:30-8 pm ET.
Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated, “We are excited to be presenting new data at the SITC meeting on COM701 and COM902, our two lead programs in our internal immuno-oncology pipeline. Our development strategy for these two programs, based on the biology of the PVRIG-TIGIT axis, includes opportunities for both monotherapy as well as dual- and triple-combination treatment options with PD-1 blockers. We see an opportunity to potentially generate significant therapeutic value for patients using our approach for drug combination.”
Following the presentations, the posters will be available on Compugen’s website at http://www.cgen.com.
About COM701 and COM902
COM701 is a humanized hybridoma antibody that binds with high affinity to PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen, blocking its interaction with PVRL2. Blockade of PVRIG by COM701 has demonstrated potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses.
COM902, Compugen’s therapeutic antibody targeting TIGIT, was developed for combination use with COM701. Preclinical data strongly support combining COM701 with TIGIT antagonist antibodies. Dual blockade of the two negative costimulatory arms of the axis - TIGIT and PVRIG - results in a more robust T cell response to antigen stimulation, and therefore may possibly result in better anti-tumor immune response. In addition, COM701 combined with antagonist anti-PD1 antibodies has demonstrated synergistic effect on human T cell stimulation, indicating the potential of these combinations to further enhance immune response against tumors.
About Compugen
Compugen is a therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company’s therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen’s business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with R&D facilities in both Israel and South San Francisco, CA. Compugen’s shares are listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen’s corporate website at http://www.cgen.com.
